Patel Nupur U, Vera Nora C, Shealy Emily Rose, Wetzel Margaret, Feldman Steven R
Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Rheumatol Ther. 2017 Dec;4(2):233-246. doi: 10.1007/s40744-017-0076-0. Epub 2017 Aug 28.
Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA. While indirect comparisons of indicate that secukinumab is as effective as other treatment options, further studies directly comparing available treatments will be necessary to establish its place in treatment guidelines. As these and other trials are conducted, the evidence produced will further elucidate the clinical potential of secukinumab as a treatment option for patients with rheumatologic disease.
银屑病关节炎（PsA）是一种与银屑病（PsO）相关的慢性、血清阴性脊柱关节炎。治疗选择范围从非药物措施到非甾体抗炎药、改善病情抗风湿药（DMARDs）和生物制剂，具体取决于患者的表现。司库奇尤单抗（可善挺©）是一种新的生物治疗选择，于2016年10月被批准用于治疗成年银屑病关节炎患者。我们的论文探讨了可用于司库奇尤单抗的临床试验证据，以检验其作为治疗银屑病关节炎治疗药物的安全性和有效性。虽然间接比较表明司库奇尤单抗与其他治疗选择一样有效，但需要进行进一步的直接比较现有治疗方法的研究，以确定其在治疗指南中的地位。随着这些及其他试验的开展，所产生的证据将进一步阐明司库奇尤单抗作为风湿病患者治疗选择的临床潜力。
